A case of autoimmune insulin antibody syndrome associated with polymyositis, empty sella and apparent high urinary output of immunoreactive insulin.
Patients with autoimmune insulin antibody are characterized by hypoglycemic attacks and antibodies to insulin in serum without prior insulin administration. In the present report, a patient with hypoglycemia due to autoimmune insulin antibody associated with primary empty sella syndrome and polymyositis appeared to have high urinary immunoreactive insulin (IRI) in the face of normal urinary C peptide. Consequently, the urinary IRI/C peptide ratio was apparently high. The amelioration of hypoglycemic attacks and polymyositis by prednisolone treatment was accompanied by the disappearance of the antibodies and complete normalization of the urinary IRI and IRI/C peptide ratio. No comparable rise in the urinary IRI and IRI/C peptide ratio was observed in the patients with other disorders studied. Glucose clamp and glucose tolerance study showed decreased sensitivity to exogenous or newly secreted insulin, prolonged half disappearance time of serum insulin, and normal disappearance of blood glucose. These results were consistent with the idea that autoantibodies buffered the effect of exogenous or newly secreted insulin and maintained a relatively constant level of serum free insulin which was not high enough when a large amount of glucose was loaded, but was too high after prolonged fasting, which eventually caused hypoglycemic attacks.
Ichikawa
K
K
Department of Geriatrics, Shinshu University School of Medicine, Matsumoto, Japan.
Nishii
Y
Y
Hashizume
K
K
Chino
M
M
Nagasawa
T
T
Suzuki
S
S
Okada
N
N
Kobayashi
M
M
Koizumi
Y
Y
Arai
M
M
D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000209:etiology*; D001786:Blood Glucose / Q000032:analysis; D002096:C-Peptide / Q000652:urine; D002648:Child; D004652:Empty Sella Syndrome / Q000150:complications* / Q000276:immunology*; D015309:Glucose Clamp Technique; D005951:Glucose Tolerance Test; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology*; D007328:Insulin / Q000378:metabolism / Q000652:urine*; D007330:Insulin Antibodies / Q000276:immunology*; D008875:Middle Aged; D009132:Muscles / Q000201:enzymology; D009220:Myositis / Q000150:complications* / Q000188:drug therapy / Q000276:immunology*; D011239:Prednisolone / Q000627:therapeutic use; D013997:Time Factors
D001323:Autoantibodies; D001786:Blood Glucose; D002096:C-Peptide; D007328:Insulin; D007330:Insulin Antibodies; D011239:Prednisolone